Overview

A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2022-06-21
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn about how food affects selpercatinib in healthy participants. The selpercatinib will be administered in fed and fasted states. Participation could last about 7 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Loxo Oncology, Inc.
Collaborator:
Eli Lilly and Company